This incremental binding efficacy correlated with the strength of the effect of the glycosylation variants on tumor cell proliferation (Figs. 3A and 4A) and survival (Figs. 3B and 4B), corroborating that the tumor-promoting cytokine-like effect of differentially glycosylated TIMP-1 was mediated by its interaction with CD63. The gene discussed is CD63; the disease is neoplasm.